Scottish biotech engineering company uFraction8 has secured £3.4m in new investment following the completion of a funding round.
Based in Falkirk with a fully-owned subsidiary in Poland, uFraction8’s microfiltration technology is designed to optimise cell and biomass production, offering a sustainable, energy-efficient alternative to traditional methods used in the production of food, feed, and bio-based products. By enhancing the scalability and affordability of bioprocessing, the company is focused on addressing critical challenges in the global bio-tech sector.
The latest investment round includes funding from the University of Edinburgh’s in-house venture investment fund Old College Capital, Scottish Enterprise, Alwyn Capital, Thia Ventures, and a grant from the Polish Agency for Enterprise Development.
The funds will be used to further commercialise uFraction8’s technology, originally developed at the University of Edinburgh’s School of Engineering. The company’s innovation provides applications across several key markets, including microalgae and bio-separation within biopharma, which are forecast to grow to $3bn and $30bn per annum by 2030 respectively. The investment capital will also support further technology development to help transform microalgae industry production processes and drastically reduce the cost of products.
Co-founded by Dr Brian Miller and Dr Monika Tomecka, uFraction8 currently employs seven people within its business in Scotland and Poznan, Poland. The company secured £2.5m investment in an earlier investment round in 2022 led by Thia Ventures.
